Navigation Links
PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
Date:9/16/2008

ANNAPOLIS, Md., Sept. 16 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Officer of PharmAthene, will present at the UBS Global Life Sciences Conference on September 25, 2008 at 1:30 p.m. in Ballroom E at The Grant Hyatt hotel in New York.

PharmAthene's presentation will be available via webcast on the company's website at http://www.PharmAthene.com. A link to access the webcast will be accessible from the Investor Relations section of the website under News & Events / Presentations. For assistance, contact Stacey Jurchison at 410-269-2610.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) - a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) - a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) - a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve

agents

-- RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
2. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
3. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
4. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
5. PharmAthene Reports First Quarter 2008 Financial Results
6. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
7. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
8. PharmAthene Reports Year-End 2007 Financial Results
9. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
10. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
11. PharmAthene to Delay Release of Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading provider of ... technology company, has implemented Genedata Biologics ™ to scale-up their bispecific antibody ... and Neurodegenerative Diseases. , The need to systematically evaluate large panels of ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation won the ... phase of the Allotrope Framework for commercial use. , The Bio-IT World Best ... only elevate the critical role of information technology in modern biomedical research, but ...
(Date:7/17/2017)... ... , ... The Academy of Model Aeronautics (AMA) will host Aviation Adventure Day ... place from 9 a.m. to 2 p.m. at the International Aeromodeling Center in Muncie, ... Adventure Day will be packed with entertaining activities for the entire family. Attendees will ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) ... of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has been ... and testing. , However, designing a custom panel for disease research requires ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):